Innoviva Specialty Therapeutics Announces IDWeek 2024 Presentations

Innoviva Specialty Therapeutics Unveils Clinical Insights at IDWeek 2024

Innoviva Specialty Therapeutics, a prominent biotech firm dedicated to breakthroughs in critical care and infectious diseases, is set to highlight its latest clinical advancements at the upcoming IDWeek 2024. This annual gathering is a cornerstone event for professionals tackling infectious diseases, occurring between October 16-19, 2024. The event will be held in Los Angeles, California, where Innoviva Specialty Therapeutics aims to present three clinical abstracts and conduct two significant oral presentations.

Key Clinical Insights from the Pipeline

David Altarac, MD, Chief Medical Officer at Innoviva Specialty Therapeutics, expressed excitement about the latest findings from their comprehensive clinical program. He stated, "Our clinical program continues to provide crucial insights from recent sub-analyses that deliver meaningful enhancements for healthcare professionals dealing with challenging antimicrobial-resistant pathogens." One of the highlights of their pipeline is zoliflodacin, which recently completed a pivotal phase 3 trial in collaboration with the Global Antibiotics Research Development Partnership. If regulatory approval is achieved, zoliflodacin could emerge as the first novel oral antibiotic for gonorrhea in decades.

Oral Presentations at IDWeek 2024

The first notable oral presentation will occur on Friday, October 18, where Dr. Altarac will discuss a growing global challenge and how a novel public-private partnership is addressing it. This presentation is timed for 8:00 am – 9:00 am PT in Petree C. The second oral presentation on Saturday, October 19, will focus on the activity of sulbactam-durlobactam in combating Acinetobacter baumannii complexities among hospitalized patients, scheduled from 10:54 am to 11:06 am PT in Room 403A.

Comprehensive Poster Sessions

In addition to the oral presentations, the company will present several posters emphasizing their innovative research. For instance, Poster #P-1103 will detail the in vitro activity of zoliflodacin against baseline Neisseria gonorrhoeae isolates in a pivotal phase 3 randomized controlled trial. Presentations will be held on Friday, October 18, during lunch hours in Hall J&K.

Pharmacometric Analyses and Surveillance

Another significant presentation, Poster #P-1251, will provide essential pharmacometric analyses aimed at supporting dose selection for zoliflodacin, a pioneering oral antibiotic designed for uncomplicated gonorrhea. It will also share insights into the surveillance of eravacycline's effectiveness against clinical pathogens globally, reflecting data collected over four years from various infection sites. This last poster session will occur concurrently in Hall J&K.

About Innoviva Specialty Therapeutics

Innoviva Specialty Therapeutics operates as a subsidiary of Innoviva, Inc. The company's mission centers on delivering leading-edge therapies in both critical care and infectious disease sectors. Through its affiliations, including La Jolla Pharmaceutical Company and Entasis Therapeutics Inc., Innoviva's product lineup includes therapies such as GIAPREZA, designed to elevate blood pressure in adults experiencing septic or other forms of shock, and XERAVA, aimed at managing complicated intra-abdominal infections. Another notable product, XACDURO, is specially formulated for treating adults with pneumonia stemming from specific strains of Acinetobacter baumannii.

For further insights into Innoviva Specialty Therapeutics and its innovative offerings, interested parties are encouraged to explore their official website.

Frequently Asked Questions

What is IDWeek 2024?

IDWeek 2024 is an annual event focusing on infectious diseases, where researchers and healthcare professionals gather to present and discuss recent advancements in the field.

What will Innoviva Specialty Therapeutics present at IDWeek 2024?

They will present data from three clinical abstracts and conduct two significant oral presentations regarding their innovative therapies.

Who is Dr. David Altarac?

Dr. David Altarac is the Chief Medical Officer at Innoviva Specialty Therapeutics and will be one of the key speakers at IDWeek 2024.

What is zoliflodacin?

Zoliflodacin is a investigational oral antibiotic being developed to treat gonorrhea, potentially marking the first new treatment option in decades.

Where can I find more information about Innoviva Specialty Therapeutics?

For more details about their products and ongoing research, you can visit Innoviva Specialty Therapeutics' official website.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.